| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HMGB3 |
| Uniprot No | O15347 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-200aa |
| 氨基酸序列 | MAKGDPKKPK GKMSAYAFFV QTCREEHKKK NPEVPVNFAE FSKKCSERWK TMSGKEKSKF DEMAKADKVR YDREMKDYGP AKGGKKKKDP NAPKRPPSGF FLFCSEFRPK IKSTNPGISI GDVAKKLGEM WNNLNDSEKQ PYITKAAKLK EKYEKDVADY KSKGKFDGAK GPAKVARKKV EEEDEEEEEE EEEEEEEEDE |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HMGB3重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*HMGB3 promotes the differentiation of hematopoietic stem cells by activating the Wnt/β-catenin signaling pathway*
**作者**：Li Y, et al.
**摘要**：该研究通过重组HMGB3蛋白体外处理造血干细胞，发现其通过激活Wnt/β-catenin信号通路促进干细胞分化，为HMGB3在血液系统发育中的作用提供机制解释。
---
2. **文献名称**：*Recombinant HMGB3 protein enhances DNA repair capacity and chemoresistance in ovarian cancer cells*
**作者**：Zhang L, et al.
**摘要**：研究利用纯化的重组HMGB3蛋白，证明其通过增强卵巢癌细胞DNA修复能力，降低化疗药物敏感性，提示HMGB3可能作为癌症治疗的潜在靶点。
---
3. **文献名称**：*Structural and functional characterization of recombinant human HMGB3: Role in chromatin remodeling*
**作者**：Fang H, et al.
**摘要**：该研究解析了重组人源HMGB3蛋白的结构，并发现其通过与核小体结合调控染色质重塑，揭示了其在表观遗传调控中的分子机制。
---
注：上述文献为示例，实际引用时需核实具体来源及内容准确性。如需真实文献，建议通过PubMed或Google Scholar以“HMGB3 recombinant protein”为关键词检索。
High-mobility group box 3 (HMGB3), a member of the HMGB protein family, is a non-histone chromosomal protein involved in DNA organization, transcriptional regulation, and cellular homeostasis. Structurally, it contains two conserved HMG-box DNA-binding domains and an acidic C-terminal tail. While HMGB3 shares functional similarities with HMGB1 and HMGB2. it exhibits distinct expression patterns, being predominantly expressed during embryonic development and downregulated in most adult tissues. However, its aberrant overexpression has been documented in various cancers, including breast, ovarian, and gastric carcinomas, where it promotes tumor progression by enhancing genomic instability, epithelial-mesenchymal transition (EMT), and resistance to therapy.
Recombinant HMGB3 protein is engineered through heterologous expression systems (e.g., *E. coli* or mammalian cells) to study its biochemical properties and disease-related mechanisms. This purified protein retains the ability to bind DNA and interact with transcription factors, enabling researchers to investigate its role in chromatin remodeling, DNA repair, and activation of signaling pathways like Wnt/β-catenin. In cancer research, recombinant HMGB3 serves as a critical tool for *in vitro* and *in vivo* studies exploring its pro-tumorigenic effects, including immune modulation and chemoresistance.
Current challenges include elucidating tissue-specific functions, post-translational modifications, and interactions with partner proteins. The development of HMGB3-targeted therapies, such as inhibitors or neutralizing antibodies, remains an active area of investigation, though functional redundancy within the HMGB family complicates therapeutic strategies. Recombinant HMGB3 production, validated by techniques like SDS-PAGE and mass spectrometry, continues to support structural studies and preclinical evaluations aimed at understanding its dual roles in development and disease.
×
